Accelerating gene therapy projects from DNA design to commercial scale

We are a science-driven contract development and manufacturing organization offering end-to-end viral vector manufacturing solutions.

DINAMIQS at a glance

View our flyer

Highly skilled team with 80+ years combined experience

  • Demonstrated track record of achievement in viral vector manufacturing
  • Experienced with multiple viral vector serotypes and scales
  • Focus on innovation
  • Deep understanding of regulatory requirements

End-to-end solutions from R&D to commercial manufacturing

  • Scalable platform including analytical solutions
  • GMP-compatible processes from early phase, reducing efforts, time and costs in transition from R&D to GMP
  • Upstream and downstream process development capabilities
  • Preclinical viral vector manufacturing from 0.5-liter to 50-liter scale
  • cGMP scale production up to 1000-liter

Customer-centric partner tailored to meet your needs

  • Integrated, efficient, and time-saving pathways
  • Close collaboration with effective communication
  • Continuous development support and assistance

Member of the Siegfried network, a globally leading CDMO

  • Full access to Siegfried’s sterile drug products manufacturing network in US and Europe
  • Full support to transform from a start-up to a best-in-class CDMO

Visit the Siegfried website.

Tackling challenges in viral vector manufacturing

Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at commercial scale is still a limitation to its broader use. Dr. Eduard Ayuso discusses how DINAMIQS works to overcome these challenges.

Read more


Update May 04, 2024
Celebrating 1 year as Siegfried DINAMIQS
Update Mar 01, 2024
DINAMIQS welcomes new CEO
Media release Feb 02, 2024
DINAMIQS Appoints New CEO and Board Member
Update Jan 18, 2024
DINAMIQS welcomes two new leadership team members
Update Dec 27, 2023
Newly launched website for Magic Horizon
Update Dec 19, 2023
Successful implementation of the Stunner
Update Dec 11, 2023
Implementing the SamuxMP mass photometer
Update Nov 06, 2023
We are open for partnerships
Update Sep 26, 2023
Setting up the AKTA Avant
Update Sep 21, 2023
Reaching a next milestone
Media release May 24, 2023
Siegfried acquires majority stake in DINAMIQS to establish a best-in-class development and manufacturing organization for cell and gene therapies


Let's get in touch

Martin Kessler
Chief Executive Officer
Vincent Zuliani
Head of Business Development
To top